当前位置： SCI文献检索 > PHARMACOLOGICAL RESEARCH期刊下所有文献 > Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Abstract：

:Metastatic cancers account for more than 90% of cancer mortality. The metastasis of all cancers is critically mediated by enzymes that degrade extracellular matrix. Aggressive tumors are characterized by an imbalance between enzymes that degrade ECM and endogenous inhibitors of the enzymes. Matrix metalloproteinases (MMPs) make up the majority of ECM degrading enzymes implicated in cancer metastasis. The potent MMP inhibitory activities of tetracyclines, especially their chemically modified analogs, combined with their relatively well tolerated pharmacological profile, led several researchers to investigate their anticancer potential in a variety of cancers, including melanoma, lung, breast and prostate cancers. Chemically modified non-antibiotic tetracyclines (CMTs or COL) were tested using tumors of prostate, breast and melanomas. Some of these CMTs, notably, CMT-3 and CMT-308 significantly inhibited not only invasive potential and MMP activity, but also inhibited cell proliferation by inducing cell cycle arrest and apoptosis. CMT-3 and CMT-308 were significantly more potent than doxycycline or minocycline in inhibiting tumor cell-derived MMPs and inducing apoptosis in vitro and in vivo. CMT-3 (COL-3) showed potent inhibition of tumor growth in xenografts and in bone metastatic models of prostate cancer. Similar results were also reported in melanoma and breast cancer models. The mechanism by which CMTs kill tumor cells is via generation of hydroxyl free radicals ([OH](-)) which permeate and depolarize mitochondria, which in turn activates caspase mediated apoptosis. Analysis of tumor tissues from CMT-3 treated rats demonstrated reduction in angiogenesis and increase in apoptosis; both emerged as mechanisms of CMT action. These observations led to testing the efficacy of CMT-3 in human clinical trials against several types of cancer with significant outcomes, which are described in the next chapter of this issue.

journal_name

Pharmacol Res

journal_title

Pharmacological research

authors

Lokeshwar BL

doi

10.1016/j.phrs.2010.11.003

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

146-50

issue

eissn

1043-6618

issn

1096-1186

pii

S1043-6618(10)00216-1

journal_volume

pub_type

杂志文章,评审

在线工具

Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.